Vimta Labs Earnings Call Transcript: Key Takeaways
Stable Q2 performance masked by R&D lulls and logistics headwinds.
- Call
- Guides 25% growth
ALFA Filings
Every announcement, straight from the exchange
Reference market data from a third-party provider, updated daily. Not a valuation or a recommendation.
Announcement type
Time
4 announcements with these filters
Stable Q2 performance masked by R&D lulls and logistics headwinds.
Q2 FY27: total income Rs1,149Mn (+9.9% YoY), EBITDA Rs408Mn (35.5% margin), PAT Rs206Mn (17.9% margin, +3.5% YoY). H1 FY27 PAT Rs417Mn (+7.3%).
Vimta Labs reported Q1 FY27 total income of INR 1,129 million, up 13.7% YoY. Strategy focuses on diversifying into Biologics (CRAD) and strengthening domestic food testing.
Vimta Labs reports 13.7% YoY revenue growth in Q1 FY27, driven by strong performance in Pharma and Food testing segments with a 36.4% EBITDA margin.